Paper No. ___ Filed: August 11, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD MNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.

v.

Petitioners,

JAZZ PHARMACEUTICALS, INC.

Patent Owner

Case IPR2015-00554

Patent 7,668,730

JAZZ PHARMACEUTICALS, INC.'S OBJECTIONS TO EVIDENCE SUBMITTED DURING THE PRELIMINARY PROCEEDING PURSUANT TO 37 C.F.R. § 42.64(b)(1)

Pursuant to 37 C.F.R. § 42.64(b)(1), Patent Owner Jazz Pharmaceuticals, Inc. objects as follows to the admissibility of evidence submitted during the preliminary proceeding:

Evidence	Objections
PAR1007 at	FRE 602: No evidence supports a finding that Dr. Valuck has
¶¶ 20, 47, 51, 152, and any other paragraph	personal knowledge of the public accessibility/availability of the
addressing the public	Advisory Committee Art (PAR1003-1006).
accessibility/ availability of	FRE 702: Dr. Valuck's assertions regarding the alleged public
PAR1003-1006	accessibility/availability of PAR1003-1006 are improper expert
	testimony at least because: (1) Dr. Valuck is not qualified as an
	expert on the subject of public accessibility/availability; (2) Dr.
	Valuck's specialized knowledge is not helpful to the trier of fact
	to understand or determine the public accessibility/availability
	of PAR1003-1006; and (3) Dr. Valuck's testimony regarding the
	alleged public accessibility/availability of PAR1003-1006 is not
	based on sufficient facts or data and is not the product of reliable
	principles and methods reliably applied by Dr. Valuck.
PAR1028	FRE 802: The exhibit is inadmissible hearsay if it is offered to
	prove the truth of the matter asserted therein, including, but not



Evidence	Objections
	limited to, any alleged public accessibility/availability of
	PAR1003-1006.
	FRE 901: Petitioners have not produced evidence sufficient to
	support a finding that the exhibit is what Petitioners claim it is.

Date: August 11, 2015 Respectfully submitted,

By: /F. Dominic Cerrito (Reg. No. 38,100)/

F. Dominic Cerrito (Reg. No. 38,100) Evangeline Shih (Reg. No. 50,170) Frank C. Calvosa (Peg. No. 60,064)

Frank C. Calvosa (Reg. No. 69,064)

QUINN EMANUEL URQUHART &

SULLIVAN, LLP

51 Madison Avenue, 22nd Floor

New York, NY 10010

General Tel: (212) 849-7000

Fax: (212) 849-7100

nickcerrito@quinnemanuel.com evangelineshih@quinnemanuel.com frankcalvosa@quinnemanuel.com

John V. Biernacki

Reg. No. 40,511

JONES DAY

North Point

901 Lakeside Avenue

Cleveland, Ohio 44114

General Tel: (216) 586-3939 Direct Tel: (216) 586-7747

Fax: (216) 579-0212

jvbiernacki@jonesday.com

Attorneys for Jazz Pharmaceuticals, Inc.



UNITED STATES PATENT AND TRADEMARK OFFICE _____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.

Petitioners,

v.

JAZZ PHARMACEUTICALS, INC.

Patent Owner

Case IPR2015-00554

Patent 7,668,730

CERTIFICATE OF SERVICE



CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that JAZZ PHARMACEUTICALS, INC.'S OBJECTIONS TO EVIDENCE SUBMITTED DURING THE PRELIMINARY PROCEEDING was served on August 11, 2015 by filing this document through the Patent Review Processing System, as well as emailing a copy to aziz.burgy@arentfox.com, bradfordfrese@arentfox.com, and XYREM@arentfox.com.

Date: August 11, 2015

Respectfully submitted,

By: /F. Dominic Cerrito (Reg. No. 38,100)/

F. Dominic Cerrito (Reg. No. 38,100) Evangeline Shih (Reg. No. 50,170) Frank C. Calvosa (Reg. No. 69,064)

QUINN EMANUEL URQUHART &

SULLIVAN, LLP

51 Madison Avenue, 22nd Floor

New York, NY 10010

General Tel: (212) 849-7000

Fax: (212) 849-7100

nickcerrito@quinnemanuel.com evangelineshih@quinnemanuel.com frankcalvosa@quinnemanuel.com

John V. Biernacki Reg. No. 40,511 JONES DAY North Point 901 Lakeside Avenue Cleveland, Ohio 44114 General Tel: (216) 586-3939

Direct Tel: (216) 586-7747

Fax: (216) 579-0212

jvbiernacki@jonesday.com

Attorneys for Jazz Pharmaceuticals, Inc.

